Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $38.00 price target on the stock.

Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Up 10.4 %

Shares of PVLA opened at $13.25 on Friday. The firm has a market cap of $17.49 million, a P/E ratio of -1.10 and a beta of 0.61. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins bought 4,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares in the company, valued at $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.39% of the company’s stock.